+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Tumour vascularity assessed using Doppler ultrasound predicts the risk of resistance to methotrexate chemotherapy in gestational trophoblastic tumours



Tumour vascularity assessed using Doppler ultrasound predicts the risk of resistance to methotrexate chemotherapy in gestational trophoblastic tumours



British Journal of Cancer 85(Suppl. 1): 26




(PDF emailed within 1 workday: $29.90)

Accession: 035991973

Download citation: RISBibTeXText


Related references

Tumor vascularity assessed by Doppler ultrasound independently predicts response to chemotherapy in patients with gestational trophoblastic tumors. Proceedings of the American Association for Cancer Research Annual Meeting 42: 49, 2001

Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy. Journal of Reproductive Medicine 55(7-8): 279-284, 2010

Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecologic Oncology 125(3): 572-575, 2012

Methotrexate combined chemotherapy for chemorefractory gestational trophoblastic tumour. Zhonghua Fu Chan Ke Za Zhi 34(2): 97-100, 2001

Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. Gynecologic Oncology 148(1): 161-167, 2017

Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia. Ultrasound in Obstetrics and Gynecology 40(1): 99-105, 2013

Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy. British Journal Of Cancer. 66(5): 883-887, 1992

Single methotrexate chemotherapy for low-risk gestational trophoblastic tumor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 25(4): 414-417, 2003

Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. Journal of Clinical Oncology 18(4): 854-859, 2000

Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database of Systematic Reviews 2006(3): Cd005196, 2006

Combination chemotherapy for high-risk gestational trophoblastic tumour. Cochrane Database of Systematic Reviews 2009(2): Cd005196, 2009

The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate. Journal of Cancer Research and Therapeutics 9(1): 38-43, 2013

Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecologic Oncology 78(1): 28-31, 2000

Treatment of high-risk gestational trophoblastic disease with methotrexate, actinomycin D, and cyclophosphamide chemotherapy. Obstetrics and Gynecology 65(6): 830-836, 1985

Etopside, methotrexate, kengshengmycin/etopside, cisplatin chemotherapy for chemorefractory gestational trophoblastic tumour. Zhonghua Fu Chan Ke Za Zhi 40(2): 79-82, 2005